Steven M Rowe1, Ginger Reeves2, Heather Hathorne2, G Martin Solomon3, Smita Abbi4, Didier Renard5, Ruth Lock6, Ping Zhou6, Henry Danahay6, John P Clancy7, David A Waltz8. 1. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL; Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, AL; Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL. Electronic address: smrowe@uab.edu. 2. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL; Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL. 3. Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL. 4. Novartis Institutes for BioMedical Research, East Hanover, NJ. 5. Novartis Institutes for BioMedical Research, Basel, Switzerland. 6. Novartis Institutes for BioMedical Research, Horsham, England. 7. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, and University of Cincinnati, Cincinnati, OH. 8. Novartis Institutes for BioMedical Research, Cambridge, MA.
Abstract
BACKGROUND: Prostasin, a trypsin-like serine protease, is a channel-activating protease and major regulator of epithelial sodium channel-mediated sodium absorption. Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF). METHODS: To determine whether a topical formulation of camostat represents an efficacious and tolerable approach to reducing Na+ transport in the CF airway, we conducted a two-part randomized, double-blind, placebo-controlled, crossover, ascending single-dose study to evaluate the pharmacodynamics, safety, and pharmacokinetics of camostat administered through a nasal spray pump in subjects with CF. Nasal potential difference (PD) was measured before and after treatment, and safety and pharmacokinetics were assessed by a standardized approach. RESULTS: In part 1, nine subjects were enrolled, and six completed crossover dosing at the maximally tolerated dose. The change in maximal (most polarizing) basal PD 2 h following administration of camostat was +13.1 mV (1.6-mg dose group) compared with -8.6 mV following placebo (P<.005). Intrasubject change in Ringer and amiloride-sensitive PDs exhibited similar and consistent responses. Bayesian analysis in an additional six subjects in part 2 estimated a dose of 18 μg/mL to provide 50% of the maximum effect. There was no significant change in chloride transport or total nasal symptom score, nasal examination rating, and laboratory parameters. CONCLUSIONS: This study establishes the proof of concept that a reduction in sodium transport in the human CF airway can be achieved through inhibition of prostasin activity, identifying a potential therapeutic target in the disease. TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT00506792; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND:Prostasin, a trypsin-like serine protease, is a channel-activating protease and major regulator of epithelial sodium channel-mediated sodium absorption. Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF). METHODS: To determine whether a topical formulation of camostat represents an efficacious and tolerable approach to reducing Na+ transport in the CF airway, we conducted a two-part randomized, double-blind, placebo-controlled, crossover, ascending single-dose study to evaluate the pharmacodynamics, safety, and pharmacokinetics of camostat administered through a nasal spray pump in subjects with CF. Nasal potential difference (PD) was measured before and after treatment, and safety and pharmacokinetics were assessed by a standardized approach. RESULTS: In part 1, nine subjects were enrolled, and six completed crossover dosing at the maximally tolerated dose. The change in maximal (most polarizing) basal PD 2 h following administration of camostat was +13.1 mV (1.6-mg dose group) compared with -8.6 mV following placebo (P<.005). Intrasubject change in Ringer and amiloride-sensitive PDs exhibited similar and consistent responses. Bayesian analysis in an additional six subjects in part 2 estimated a dose of 18 μg/mL to provide 50% of the maximum effect. There was no significant change in chloride transport or total nasal symptom score, nasal examination rating, and laboratory parameters. CONCLUSIONS: This study establishes the proof of concept that a reduction in sodium transport in the human CF airway can be achieved through inhibition of prostasin activity, identifying a potential therapeutic target in the disease. TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT00506792; URL: www.clinicaltrials.gov.
Authors: J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou Journal: Science Date: 1989-09-08 Impact factor: 47.728
Authors: Mark R Elkins; Michael Robinson; Barbara R Rose; Colin Harbour; Carmel P Moriarty; Guy B Marks; Elena G Belousova; Wei Xuan; Peter T P Bye Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Scott H Donaldson; William D Bennett; Kirby L Zeman; Michael R Knowles; Robert Tarran; Richard C Boucher Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: M R Knowles; N L Church; W E Waltner; J R Yankaskas; P Gilligan; M King; L J Edwards; R W Helms; R C Boucher Journal: N Engl J Med Date: 1990-04-26 Impact factor: 91.245
Authors: Michael Wilschanski; Annie Dupuis; Lynda Ellis; Keith Jarvi; Julian Zielenski; Elizabeth Tullis; Sheelagh Martin; Mary Corey; Lap-Chee Tsui; Peter Durie Journal: Am J Respir Crit Care Med Date: 2006-07-13 Impact factor: 21.405
Authors: T Hofmann; M J Stutts; A Ziersch; C Rückes; W M Weber; M R Knowles; H Lindemann; R C Boucher Journal: Am J Respir Crit Care Med Date: 1998-06 Impact factor: 21.405
Authors: Carey A Hobbs; Maxime G Blanchard; Stephan Kellenberger; Sompop Bencharit; Rui Cao; Mehmet Kesimer; William G Walton; Matthew R Redinbo; M Jackson Stutts; Robert Tarran Journal: FASEB J Date: 2012-07-13 Impact factor: 5.191
Authors: Richard C Ahrens; Thomas A Standaert; Janice Launspach; Seung-Ho Han; Mary E Teresi; Moira L Aitken; Thomas J Kelley; Kathleen A Hilliard; Laura J H Milgram; Michael W Konstan; Mark R Weatherly; Nael A McCarty Journal: Pediatr Pulmonol Date: 2002-02
Authors: George M Solomon; Bo Liu; Isabelle Sermet-Gaudelus; Isabelle Fajac; Michael Wilschanski; Francois Vermeulen; Steven M Rowe Journal: J Cyst Fibros Date: 2017-04-29 Impact factor: 5.482
Authors: Olivier Bardou; Awen Menou; Charlène François; Jan Willem Duitman; Jan H von der Thüsen; Raphaël Borie; Katiuchia Uzzun Sales; Kathrin Mutze; Yves Castier; Edouard Sage; Ligong Liu; Thomas H Bugge; David P Fairlie; Mélanie Königshoff; Bruno Crestani; Keren S Borensztajn Journal: Am J Respir Crit Care Med Date: 2016-04-15 Impact factor: 21.405
Authors: Katherine C Jankousky; Jonathan Schultz; Samuel Windham; Andrés F Henao-Martínez; Carlos Franco-Paredes; Leland Shapiro Journal: Ther Adv Infect Dis Date: 2020-06-10
Authors: George M Solomon; Carla Frederick; Shaoyan Zhang; Amit Gaggar; Tom Harris; Bradford A Woodworth; Chad Steele; Steven M Rowe Journal: PLoS One Date: 2013-08-16 Impact factor: 3.240
Authors: Niroop Kaza; S Vamsee Raju; Joan M Cadillac; John A Trombley; Lawrence Rasmussen; Liping Tang; Erik Dohm; Kevin S Harrod; Steven M Rowe Journal: PLoS One Date: 2017-10-27 Impact factor: 3.240